C4 Therapeutics (CCCC) to Release Quarterly Earnings on Thursday

C4 Therapeutics (NASDAQ:CCCC) is projected to issue its quarterly earnings data on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.45) per share and revenue of $4.33 million for the quarter.

C4 Therapeutics Trading Up 0.9 %

C4 Therapeutics stock opened at $3.30 on Thursday. The stock has a market cap of $232.94 million, a P/E ratio of -1.94 and a beta of 2.95. The stock has a 50 day moving average of $3.83 and a 200-day moving average of $5.07. C4 Therapeutics has a 52 week low of $3.16 and a 52 week high of $11.88.

Analysts Set New Price Targets

CCCC has been the subject of several research analyst reports. Stephens started coverage on C4 Therapeutics in a research note on Monday, November 18th. They set an “equal weight” rating and a $4.00 target price for the company. Wells Fargo & Company raised C4 Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $8.00 to $12.00 in a research report on Thursday, December 19th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, C4 Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $11.60.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.